These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 26327760)

  • 1. Interferon-free regimens for the treatment of hepatitis C virus in liver transplant candidates or recipients.
    Cholongitas E; Pipili C; Papatheodoridis G
    World J Gastroenterol; 2015 Aug; 21(32):9526-33. PubMed ID: 26327760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
    Bailly F; Pradat P; Virlogeux V; Zoulim F
    Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hepatitis C infection before and after liver transplantation.
    Fagiuoli S; Ravasio R; Lucà MG; Baldan A; Pecere S; Vitale A; Pasulo L
    World J Gastroenterol; 2015 Apr; 21(15):4447-56. PubMed ID: 25914454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New hepatitis C virus therapies: drug classes and metabolism, drug interactions relevant in the transplant settings, drug options in decompensated cirrhosis, and drug options in end-stage renal disease.
    Kwo PY; Badshah MB
    Curr Opin Organ Transplant; 2015 Jun; 20(3):235-41. PubMed ID: 25944238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection.
    Weiler N; Zeuzem S; Welker MW
    World J Gastroenterol; 2016 Nov; 22(41):9044-9056. PubMed ID: 27895394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Direct-acting Antivirals to Improve Clinical Condition, Fibrosis, and Liver Function in Liver Transplant Recipients Infected by Hepatitis C.
    Garcia-Pajares F; Tejedor-Tejada J; Torres-Yuste R; Almohalla-Alvárez C; Sánchez-Ocaña R; Peñas-Herrero I; Cimavilla-Román M; de Benito-Sanz M; Sánchez-Martín F; Sánchez-Antolín G
    Transplant Proc; 2019; 51(1):74-76. PubMed ID: 30655151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. INF-free sofosbuvir-based treatment of post-transplant hepatitis C relapse - a Swedish real life experience.
    Castedal M; Segenmark M; Cederberg S; Skoglund C; Weiland O
    Scand J Gastroenterol; 2017 May; 52(5):585-588. PubMed ID: 28270038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
    Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
    Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study.
    Saxena V; Khungar V; Verna EC; Levitsky J; Brown RS; Hassan MA; Sulkowski MS; O'Leary JG; Koraishy F; Galati JS; Kuo AA; Vainorius M; Akushevich L; Nelson DR; Fried MW; Terrault N; Reddy KR
    Hepatology; 2017 Oct; 66(4):1090-1101. PubMed ID: 28504842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
    Iacob S; Cerban R; Pietrareanu C; Ester C; Iacob R; Gheorghe C; Popescu I; Gheorghe L
    J Gastrointestin Liver Dis; 2018 Jun; 27(2):139-144. PubMed ID: 29922758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
    Calleja JL; Crespo J; Rincón D; Ruiz-Antorán B; Fernandez I; Perelló C; Gea F; Lens S; García-Samaniego J; Sacristán B; García-Eliz M; Llerena S; Pascasio JM; Turnes J; Torras X; Morillas RM; Llaneras J; Serra MA; Diago M; Rodriguez CF; Ampuero J; Jorquera F; Simon MA; Arenas J; Navascues CA; Bañares R; Muñoz R; Albillos A; Mariño Z;
    J Hepatol; 2017 Jun; 66(6):1138-1148. PubMed ID: 28189751
    [TBL] [Abstract][Full Text] [Related]  

  • 12.  Sofosbuvir and daclatasvir in mono- and HIV-coinfected patients with recurrent hepatitis C after liver transplant.
    Castells L; Llaneras J; Campos-Varela I; Bilbao I; Crespo M; Len O; Rodríguez-Frías F; Charco R; Salcedo T; Esteban JI; Esteban-Mur R
    Ann Hepatol; 2017 Jan-Feb 2017; 16(1):86-93. PubMed ID: 28051797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential Liver Transplant Recipients with Hepatitis C: Should They Be Treated Before or After Transplantation?
    Anand AC
    J Clin Exp Hepatol; 2017 Mar; 7(1):42-54. PubMed ID: 28348470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, Safety, and Predictors of Direct-acting antivirals in Hepatitis C Virus Patients with Heterogeneous Liver Diseases.
    De Pace V; Morelli MC; Ravaioli M; Maggi F; Galli S; Vero V; Re MC; Cescon M; Pistello M
    New Microbiol; 2019 Oct; 42(4):189-196. PubMed ID: 31609453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of Chronic Hepatitis C in Special Populations.
    Bunchorntavakul C; Tanwandee T
    Gastroenterol Clin North Am; 2015 Dec; 44(4):883-900. PubMed ID: 26600226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
    Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
    World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-Free Hepatitis C Treatment before and after Liver Transplantation: The Role of HCV Drug Resistance.
    Roche B; Coilly A; Roque-Afonso AM; Samuel D
    Viruses; 2015 Sep; 7(9):5155-68. PubMed ID: 26404355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of severe recurrent hepatitis C after liver transplantation in HIV infected patients using sofosbuvir-based therapy.
    Campos-Varela I; Moreno A; Morbey A; Guaraldi G; Hasson H; Bhamidimarri KR; Castells L; Grewal P; Baños I; Bellot P; Brainard DM; McHutchison JG; Terrault NA
    Aliment Pharmacol Ther; 2016 Jun; 43(12):1319-29. PubMed ID: 27098374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos in.
    Price JC; Terrault NA
    Liver Transpl; 2015 Apr; 21(4):423-34. PubMed ID: 25604355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.